Dr. Ernie Reimer, chair of the board of directors for Genome Atlantic is pleased to announce the appointment of Dr. Steven Armstrong as the new president and CEO effective April 1, 2007.

As a former research associate with the Ontario Cancer Treatment and Research Foundation/McMaster University, a former consultant with CanTox Health Sciences International, and as the former director of the Life Sciences Industry Partnership at Innovacorp, Dr. Armstrong has a great deal of experience both locally and nationally within the life sciences sector. His career to date includes a Ph.D. in pharmacology from Dalhousie University, training and experience in project and intellectual property management, as well as contract negotiation. Steve’s most recent position has been as the vice president of research and business development at Genome Atlantic.

"Dr. Armstrong brings a depth of science and business management experience to Genome Atlantic’s ongoing partnership with Genome Canada, supporting scientific excellence in genomics and working to bring social and economic benefits to the region,” says Dr. Reimer.

Dr. Armstrong replaces Dr. Michael Dennis who, after more than three years in the position, is moving on to pursue a commercial venture in environmental biotech, enabled in part by Genome Atlantic investments to date in microbial genomics. Under his leadership, Genome Atlantic managed the successful completion of established projects valued at $17 million and, with Genome Atlantic’s regional partners, raised over $25 million in funding to support new initiatives in Atlantic Canada. This included two new large-scale genomics research projects focused on cod aquaculture and human genetic diseases, as well as the establishment of the Atlantic Genome Centre (TAGC) as a regional centre for genomics R&D.

"Dr. Dennis established high standards for project management and for the pursuit of tangible outcomes,” says Dr. Reimer. “His transition to the private sector furthers one of Genome Atlantic's regional objectives."

With over $40 million committed to projects to date, Genome Atlantic invests in and supports the management of outstanding genomics research with commercial potential. Funding partners include Genome Canada, the Atlantic Canada Opportunities Agency, the provincial governments of Nova Scotia, New Brunswick and Newfoundland and Labrador, several industry partners, and various provincial and federal innovation and research organizations.




For more information, please contact:
Jill Murrin
Genome Atlantic

Halifax, Nova Scotia, April 13, 2007